Company History and Chronology

Greystone Pharmaceuticals, Inc., was founded in 1996 by Gregory P. Pilant to investigate and commercialize new wound-healing technologies – both natural and synthetic – and license them for distribution. The Company’s Corporate Headquarters is located in Fort Myers, Florida; its Operations and Manufacturing facilities are located in Memphis, Tennessee; and its Research & Development facilities are in Richmond, Virginia. The EU headquarters for Greystone Pharmaceuticals, Inc. is located in Kaatsheuvel, The Netherlands.

1995
Greg Pilant, Greystone Pharmaceuticals, Inc.’s founder and CEO, is introduced to a wound treatment made from botanical oak bark extract.

2001
More than five years and millions of dollars later, Greystone Pharmaceuticals, Inc. isolates the active ingredients in the botanical formulation that are responsible for wound healing. Soon after, Greystone Pharmaceuticals, Inc. begins a series of scientific and clinical studies in Europe to investigate the mechanism of action of the products and to test their efficacy and safety in human subjects.

2002
DerMax® is approved as a Class IIa medical device in the EU. After the submission of additional clinical and scientific data, DerMax® is reclassified as a Class IIb medical device. DerMax® is launched in 21 countries.

2005
Epi-Max® is cleared for sale in the United States by the FDA as a combination product governed by the medical device regulation 510(k). MelMax® is launched in Europe and the Middle East.